Volume 19, Number 2—February 2013
Macrolide- and Rifampin-Resistant Rhodococcus equi on a Horse Breeding Farm, Kentucky, USA
|Foal ID no.||Pretreatment isolates (cluster)||% Similarity†||Posttreatment isolates (cluster)|
|14-11||R (E)||96.4||R (E)|
|3-11||R (B)||96.5||R (B)|
|4-11||R (B)||97.4||R (B)|
|17-11||R (C)||98.5||R (C)|
*ID, identification; S, susceptible; R, resistant; NA, not applicable.
†Determined by using Pearson correlation coefficient and unweighted pair-group method with arithmetic means.
‡Two isolates were recovered from the pretreatment (foal ID 16-11) or posttreatment (foal ID 15-11) sampling.
1Current affiliation: Kalon Biotherapeutics LLC, College Station, Texas, USA.
- Page created: January 22, 2013
- Page last updated: January 22, 2013
- Page last reviewed: January 22, 2013
- Centers for Disease Control and Prevention,
National Center for Emerging and Zoonotic Infectious Diseases (NCEZID)
Office of the Director (OD)